Age-resolved mouse disease series
Complement transcripts, proteins, synaptic markers, and tau pathology are examined at 2, 4, and 6 months, covering the model's reported progression window.
↳ Methods, Animals; Results, Figs. 1–7
Abstract
Synapse loss is the best correlate of cognitive decline in neurodegenerative diseases (NDDs). In Alzheimer's disease complement dysregulation, triggered by amyloid-β accumulation, plays a major role in synapse loss, but its contribution in other NDDs where amyloid is absent, most notably tauopathies, is elusive. Aggregation of tau is a prominent co-pathology in many NDDs and is characteristic of classical tauopathies in which amyloid pathology is lacking. Here we explore the effect of tau accumulation on complement dysregulation and its contribution to neuronal damage and synapse loss in a mouse tauopathy model harbouring the familial P301S tau mutation and post-mortem brain samples from human tauopathies. Complement gene and protein expression were analysed in P301S mice at 2, 4 and 6 M of age. Complement dysregulation was evident from qPCR analysis showing increased classical pathway (C4, C2), and complement receptor (C3ar1, Cd11b, Cd11c) gene expression in P301S mice compared to wildtype (WT). C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates. Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates. The classic pathway regulator CSMD1 was present on synapses and decreased on C1q positive synapses in P301S mice, implying a loss of protection from complement attack. Observations in human tauopathy brains demonstrated decreased CSMD1-labelled excitatory synapses, consistent with findings in P301S mice. These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.
Key Claims
Primary findingTentative
These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
causal contribution is inferred from associative mouse and post-mortem comparisons without a complement intervention
Abstract, final sentence; Conclusion
SecondarySupported
C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates.
large directional differences are reported, although incompatible ANOVA details reduce confidence in exact inference
Abstract; Results, Figs. 3–4
SecondaryTentative
Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates.
Fig. 6 reports fewer C1q-positive synapses around tau-positive neurons, contradicting the proximity wording
Abstract; Results, Figs. 5–6
SecondaryTentative
The classic pathway regulator CSMD1 was present on synapses and decreased on C1q positive synapses in P301S mice, implying a loss of protection from complement attack.
CSMD1 differences are associative and absent at six months, with no functional perturbation of protection
Abstract; Results, Fig. 7
SecondarySupported
in GGT cases there was a significant reduction in the percentage of total CSMD1 labelled synapses ... compared to healthy controls.
the reported direction is GGT-specific and rests on four heterogeneous post-mortem cases
Results, CSMD1 positive synapses are decreased in human tauopathies; Fig. 8
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
CSMD1 adds a distinct angle
The study assesses a classical-pathway regulator at synapses in P301S mice and extends that measurement to CBD and GGT tissue, providing an incremental addition to prior C1q-focused work.
↳ Results, Figs. 7–8; Discussion, CSMD1 paragraphs
Relevant prior studies are engaged
The article discusses earlier P301S complement-expression findings and C1q/C3 knockout studies, distinguishing the present descriptive work from existing functional evidence.
↳ Introduction, paragraph 2; Discussion, paragraphs 1 and 5
Limitations
Central statistics are internally inconsistent
Fig. 3 reports incompatible F and p values and anomalous factor degrees of freedom; Fig. 4 gives two correlation coefficients, and Fig. 2 conflicts with the Results on Cd11b timing. These defects require correction before the quantitative findings can be relied upon.
↳ Results and legends for Figs. 2–4
Conclusions exceed associative evidence
The study does not manipulate complement or CSMD1, yet the Conclusion attributes resultant synapse loss to classical-pathway dysregulation in mice and humans. Fig. 8 reports no significant human synapse-density difference.
↳ Results, Fig. 8; Conclusion
Human validation is narrow and heterogeneous
The post-mortem groups are small and contain multiple co-pathologies, while the CSMD1 difference is significant only in GGT and is measured on total Bassoon-positive synapses rather than excitatory synapses.
↳ Methods, Human brain tissue; Table 1; Results and Fig. 8
Nabu Commentary
The age-resolved mouse design and synaptic CSMD1 measurements provide a real but incremental addition to established complement work in P301S mice. The principal score constraint is quantitative coherence: Fig. 3 contains an incompatible F/p pairing and anomalous degrees of freedom, while Figs. 2 and 4 contain additional internal conflicts. The Abstract and Conclusion also overgeneralise the spatial and human findings, because Fig. 6 reports fewer C1q-positive synapses near tau-positive neurons and Fig. 8 shows neither human synapse loss nor a CBD CSMD1 effect. The study is therefore best treated as hypothesis-generating pending statistical correction and direct complement or CSMD1 perturbation.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Limited2.6
Confidence mediumContribution
3.0
The study adds age-resolved complement measurements and synaptic CSMD1 observations to an already established P301S complement literature. The advance is incremental because prior work had reported complement upregulation and knockout-associated protection, while the human extension is significant only for GGT.
Introduction, paragraphs 2–3; Results, Figs. 2–8
Whether complement directly causes synaptic dysfunction and loss is uncertain
Methodological Rigour
2.0
Per-mouse summaries, age-matched WT groups, both sexes, sourced reagents, and defined image-analysis thresholds support the design, but blinding and randomisation are unreported. Incompatible Fig. 3 statistics, uncertainty around the correlation unit, uncontrolled human heterogeneity, and causal interpretation of associative results substantially undermine execution.
Methods, Animals, Image analysis, and Statistics; Fig. 3 legend; Fig. 4f; Conclusion
may be attributed to complement classical pathway dysregulation
Reporting
2.8
The gene-to-protein-to-synapse-to-human sequence is easy to follow. Central wording is nevertheless misleading where the Abstract conflicts with Fig. 6 and characterises human CSMD1 measurements as excitatory-synapse findings despite Fig. 8 using total Bassoon-positive synapses.
Abstract; Results and Fig. 6; Results and Fig. 8; Conclusion
unaffected by proximity to tau aggregates
Positioning
3.3
The paper engages prior P301S C1q/C3 knockout studies and acknowledges that post-mortem tissue represents advanced disease. It does not fully trace model limitations, human co-pathologies, the null human synapse-density result, or the observational design through to the conclusion.
Introduction, paragraph 2; Discussion, final paragraph; Table 1; Conclusion
Post-mortem samples from human tauopathy cases inevitably represent advanced disease stages
Reliability
Concerns4 of 4 checks
Internal CoherenceConcern
Multiple numerical and claim-level inconsistencies affect central molecular, synaptic, and human-tissue results. The defects exceed typographical watch-outs because at least one reported F/p pairing is mathematically incompatible and several conclusions conflict with the reported analyses.
Research ConductClean
Animal and human-tissue ethics approvals are declared, and the supplied text demonstrates no conduct concern. Missing conflict, data-availability, code, and supplementary verification information remains unverified rather than adverse.
Flags: 1 declared / 5 total
Reference IntegrityNoted
27 references in manuscript 27 of 27 checkable references found in an index the reference list may be incompletely parsed; counts are indicative
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 08 Oct 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
The work characterises associations in a transgenic model and post-mortem tissue but does not test a complement or CSMD1 intervention. It therefore remains several stages before therapeutic proof of concept.
Methods, Animals and Human brain tissue; Conclusion
may also have a role in therapy of tauopathies
AI-generated, human-governed. Something look off? Contact us to request a review.